Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. develops clinical-stage therapies for unmet medical needs, with news centered on pipeline progress, regulatory authorizations, intellectual property and financing activity. Company updates frequently cover HT-001, a topical therapeutic for EGFR inhibitor-associated skin toxicities in cancer patients, as well as HT-VA/GDNF metabolic research tied to obesity, MAFLD and related liver-fat pathways.
Other HOTH news themes include patent protection for mast-cell targeting splice-switching oligonucleotide technology, use of the OpenClaw AI-enabled platform for drug-discovery analysis, and capital formation through registered direct offerings and warrant issuances. The company’s public updates generally reflect early-stage pharmaceutical research moving from preclinical work into clinical development.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that the FDA granted a Pre-IND meeting regarding HT-001, a topical treatment for rash and skin disorders in cancer patients. The meeting, requested on December 22, 2020, will provide FDA feedback on the drug development program, clinical trial designs, and necessary requirements. Feedback is expected by February 22, 2021. CEO Robb Knie expressed hope that the feedback will help expedite HT-001's transition to clinical trials, emphasizing the importance of these developments for the company's future.
On January 11, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Charles River Laboratories to conduct preclinical studies for HT-001, a topical treatment aimed at alleviating rash and skin disorders from EGFR inhibitor cancer therapies. Six preclinical studies are planned, beginning with bioanalytical method development in Q1 2021. The studies aim to fulfill FDA requirements for clinical trial initiation. Hoth's CEO emphasized the collaboration's importance in addressing significant unmet needs in dermatological care.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a definitive securities purchase agreement for a private placement to institutional investors, expected to generate approximately $5.0 million in gross proceeds. Investors will acquire 2,475,248 shares of Common Stock at $2.02, along with warrants for an additional 1,237,624 shares at an exercise price of $2.25. The placement, facilitated by The Benchmark Company, LLC, is set to close on January 7, 2021, subject to customary conditions. The securities, not registered under the Securities Act, may not be resold in the U.S. without appropriate registration.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command for a new antibacterial drug, HT-006, targeting serious lung infections like hospital-acquired pneumonia. The drug aims to combat multi-drug resistant bacteria and will benefit from streamlined development through the FDA's program for unmet medical needs. Preclinical studies are set to commence in Q1 2021, leveraging U.S. Army expertise and resources during development.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a production agreement with Tergus Pharma for GLP and GMP materials related to its cancer treatment drug, HT-001. This follows their request for a Pre-Investigational New Drug meeting with the FDA regarding HT-001, which targets skin disorders associated with EGFR inhibitor therapy. Hoth aims to alleviate dose-limiting skin toxicities, thus enhancing patient outcomes in cancer treatments. CEO Robb Knie expressed optimism for the drug's development and its potential to benefit patients.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has requested a Pre-Investigational New Drug (IND) meeting with the FDA regarding HT-001, a topical treatment aimed at addressing skin disorders from epidermal growth factor receptor (EGFR) inhibitor therapy. Over 50% of cancer patients on EGFR inhibitors experience dermatological side effects, impacting their treatment. HT-001 seeks to improve these patients' quality of life. Currently in preclinical development, the company plans to discuss clinical trial designs in its upcoming FDA meeting scheduled for Q1 2021.
Hoth (NASDAQ: HOTH) has partnered with Zylö Therapeutics to co-develop a topical treatment for Cutaneous Lupus Erythematosus (CLE), utilizing a patented delivery system called Z-pods™. The drug HT-005, targeting the endocannabinoid pathway, showed proof-of-concept efficacy in reducing skin plaques during a study in MRL/MpJ-Faslpr/J mice. This collaboration aims to address the limited therapeutic options available for CLE, which significantly impacts patient quality of life.
Hoth Therapeutics (NASDAQ: HOTH) has secured Human Research Ethics Committee (HREC) clearance to initiate its Phase 1b clinical trial of BioLexa Lotion for treating mild to moderate atopic dermatitis in Australia. Dosing of the first subject is expected early 2021, with top-line data anticipated in Q1 2021. The trial aims to evaluate the safety and pharmacokinetics of BioLexa, with preliminary efficacy assessed in a second patient cohort. CEO Robb Knie emphasized the milestone as crucial for submitting data for future FDA considerations.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising preclinical data for its therapy HT-005 targeting Cutaneous Lupus Erythematosus (CLE). Conducted by Jackson Laboratory with Zylö Therapeutics, results showed a significant reduction in skin plaque severity in mice after using HT-005-loaded topical Z-pods™. Improvements were observed within 3 weeks and maintained through 10 weeks. CEO Robb Knie expressed optimism about the therapeutic's potential addressing a high unmet need in CLE.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced key milestones in its COVID-19 product development. The company is progressing with its HT-002 peptide therapeutic aimed at treating COVID-19 symptoms, with inhibition test data expected in December 2020. The On-the-Go SARS-CoV-2 Testing Device is in research, aiming for proof-of-concept data by year-end 2020. Additionally, the VaxCelerate vaccine platform shows promise in animal models, with further preclinical studies planned. Hoth is focused on rapid development to address critical medical needs in COVID-19.